ID   SHIP2_RAT               Reviewed;        1257 AA.
AC   Q9WVR3; Q9R1V2;
DT   11-SEP-2007, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1999, sequence version 1.
DT   02-OCT-2024, entry version 147.
DE   RecName: Full=Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2 {ECO:0000305};
DE            EC=3.1.3.86 {ECO:0000269|PubMed:11238900};
DE   AltName: Full=Inositol polyphosphate phosphatase-like protein 1 {ECO:0000250|UniProtKB:O15357};
DE            Short=INPPL-1 {ECO:0000250|UniProtKB:O15357};
DE   AltName: Full=Protein 51C {ECO:0000250|UniProtKB:O15357};
DE   AltName: Full=SH2 domain-containing inositol 5'-phosphatase 2 {ECO:0000250|UniProtKB:O15357};
DE            Short=SH2 domain-containing inositol phosphatase 2 {ECO:0000250|UniProtKB:O15357};
DE            Short=SHIP-2 {ECO:0000250|UniProtKB:O15357};
GN   Name=Inppl1 {ECO:0000312|RGD:68396};
GN   Synonyms=Ship2 {ECO:0000303|PubMed:10381377};
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, AND PHOSPHORYLATION.
RC   STRAIN=Sprague-Dawley;
RX   PubMed=10381377; DOI=10.1006/bbrc.1999.0888;
RA   Ishihara H., Sasaoka T., Hori H., Wada T., Hirai H., Haruta T.,
RA   Kobayashi M.;
RT   "Molecular cloning of rat SH2-containing inositol phosphatase 2 (SHIP2) and
RT   its role in the regulation of insulin signaling.";
RL   Biochem. Biophys. Res. Commun. 260:265-272(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=10648902; DOI=10.1016/s0169-328x(99)00311-3;
RA   Kudo M., Saito S., Owada Y., Suzaki H., Kondo H.;
RT   "Localization of mRNA for SHIP2, SH2 domain-containing inositol
RT   polyphosphate 5-phosphatase, in the brain of developing and mature rats.";
RL   Brain Res. Mol. Brain Res. 75:172-177(2000).
RN   [3]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=11238900; DOI=10.1128/mcb.21.5.1633-1646.2001;
RA   Wada T., Sasaoka T., Funaki M., Hori H., Murakami S., Ishiki M., Haruta T.,
RA   Asano T., Ogawa W., Ishihara H., Kobayashi M.;
RT   "Overexpression of SH2-containing inositol phosphatase 2 results in
RT   negative regulation of insulin-induced metabolic actions in 3T3-L1
RT   adipocytes via its 5'-phosphatase catalytic activity.";
RL   Mol. Cell. Biol. 21:1633-1646(2001).
RN   [4]
RP   FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF TYR-987.
RX   PubMed=12351701; DOI=10.1210/me.2002-0083;
RA   Ishihara H., Sasaoka T., Ishiki M., Wada T., Hori H., Kagawa S.,
RA   Kobayashi M.;
RT   "Membrane localization of Src homology 2-containing inositol 5'-phosphatase
RT   2 via Shc association is required for the negative regulation of insulin
RT   signaling in Rat1 fibroblasts overexpressing insulin receptors.";
RL   Mol. Endocrinol. 16:2371-2381(2002).
RN   [5]
RP   FUNCTION.
RX   PubMed=17535963; DOI=10.1083/jcb.200609017;
RA   Aoki K., Nakamura T., Inoue T., Meyer T., Matsuda M.;
RT   "An essential role for the SHIP2-dependent negative feedback loop in
RT   neuritogenesis of nerve growth factor-stimulated PC12 cells.";
RL   J. Cell Biol. 177:817-827(2007).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-132, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
RN   [7]
RP   VARIANT CYS-1142, AND POLYMORPHISM.
RX   PubMed=12086927; DOI=10.2337/diabetes.51.7.2012;
RA   Marion E., Kaisaki P.J., Pouillon V., Gueydan C., Levy J.C., Bodson A.,
RA   Krzentowski G., Daubresse J.-C., Mockel J., Behrends J., Servais G.,
RA   Szpirer C., Kruys V., Gauguier D., Schurmans S.;
RT   "The gene INPPL1, encoding the lipid phosphatase SHIP2, is a candidate for
RT   type 2 diabetes in rat and man.";
RL   Diabetes 51:2012-2017(2002).
CC   -!- FUNCTION: Phosphatidylinositol (PtdIns) phosphatase that specifically
CC       hydrolyzes the 5-phosphate of phosphatidylinositol-3,4,5-trisphosphate
CC       (PtdIns(3,4,5)P3) to produce PtdIns(3,4)P2, thereby negatively
CC       regulating the PI3K (phosphoinositide 3-kinase) pathways
CC       (PubMed:11238900, PubMed:17535963). Required for correct mitotic
CC       spindle orientation and therefore progression of mitosis (By
CC       similarity). Plays a central role in regulation of PI3K-dependent
CC       insulin signaling, although the precise molecular mechanisms and
CC       signaling pathways remain unclear (PubMed:11238900). While
CC       overexpression reduces both insulin-stimulated MAP kinase and Akt
CC       activation, its absence does not affect insulin signaling or GLUT4
CC       trafficking (PubMed:10381377, PubMed:12351701). Confers resistance to
CC       dietary obesity (By similarity). May act by regulating AKT2, but not
CC       AKT1, phosphorylation at the plasma membrane (By similarity). Part of a
CC       signaling pathway that regulates actin cytoskeleton remodeling (By
CC       similarity). Required for the maintenance and dynamic remodeling of
CC       actin structures as well as in endocytosis, having a major impact on
CC       ligand-induced EGFR internalization and degradation (By similarity).
CC       Participates in regulation of cortical and submembraneous actin by
CC       hydrolyzing PtdIns(3,4,5)P3 thereby regulating membrane ruffling (By
CC       similarity). Regulates cell adhesion and cell spreading (By
CC       similarity). Required for HGF-mediated lamellipodium formation, cell
CC       scattering and spreading (By similarity). Acts as a negative regulator
CC       of EPHA2 receptor endocytosis by inhibiting via PI3K-dependent Rac1
CC       activation (By similarity). Acts as a regulator of neuritogenesis by
CC       regulating PtdIns(3,4,5)P3 level and is required to form an initial
CC       protrusive pattern, and later, maintain proper neurite outgrowth
CC       (PubMed:17535963). Acts as a negative regulator of the FC-gamma-RIIA
CC       receptor (FCGR2A) (By similarity). Mediates signaling from the FC-
CC       gamma-RIIB receptor (FCGR2B), playing a central role in terminating
CC       signal transduction from activating immune/hematopoietic cell receptor
CC       systems (By similarity). Involved in EGF signaling pathway (By
CC       similarity). Upon stimulation by EGF, it is recruited by EGFR and
CC       dephosphorylates PtdIns(3,4,5)P3 (By similarity). Plays a negative role
CC       in regulating the PI3K-PKB pathway, possibly by inhibiting PKB activity
CC       (By similarity). Down-regulates Fc-gamma-R-mediated phagocytosis in
CC       macrophages independently of INPP5D/SHIP1 (By similarity). In
CC       macrophages, down-regulates NF-kappa-B-dependent gene transcription by
CC       regulating macrophage colony-stimulating factor (M-CSF)-induced
CC       signaling (By similarity). Plays a role in the localization of AURKA
CC       and NEDD9/HEF1 to the basolateral membrane at interphase in polarized
CC       cysts, thereby mediates cell cycle homeostasis, cell polarization and
CC       cilia assembly (By similarity). Additionally promotion of cilia growth
CC       is also facilitated by hydrolysis of (PtdIns(3,4,5)P3) to PtdIns(3,4)P2
CC       (By similarity). Promotes formation of apical membrane-initiation sites
CC       during the initial stages of lumen formation via Rho family-induced
CC       actin filament organization and CTNNB1 localization to cell-cell
CC       contacts (By similarity). May also hydrolyze PtdIns(1,3,4,5)P4, and
CC       could thus affect the levels of the higher inositol polyphosphates like
CC       InsP6. Involved in endochondral ossification (By similarity).
CC       {ECO:0000250|UniProtKB:F1PNY0, ECO:0000250|UniProtKB:O15357,
CC       ECO:0000250|UniProtKB:Q6P549, ECO:0000269|PubMed:10381377,
CC       ECO:0000269|PubMed:11238900, ECO:0000269|PubMed:12351701,
CC       ECO:0000269|PubMed:17535963}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5-
CC         trisphosphate) + H2O = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-
CC         inositol-3,4-bisphosphate) + phosphate; Xref=Rhea:RHEA:25528,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:57658,
CC         ChEBI:CHEBI:57836; EC=3.1.3.86;
CC         Evidence={ECO:0000269|PubMed:11238900};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:25529;
CC         Evidence={ECO:0000305|PubMed:11238900};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5-
CC         trisphosphate) + H2O = 1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo-
CC         inositol-3,4-bisphosphate) + phosphate; Xref=Rhea:RHEA:43548,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:83416,
CC         ChEBI:CHEBI:83417; Evidence={ECO:0000250|UniProtKB:O15357};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43549;
CC         Evidence={ECO:0000250|UniProtKB:O15357};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-dihexadecanoyl-sn-glycero-3-phospho-(1D-myo-inositol-
CC         3,4,5-trisphosphate) + H2O = 1,2-dihexadecanoyl-sn-glycero-3-phospho-
CC         (1D-myo-inositol-3,4-bisphosphate) + phosphate; Xref=Rhea:RHEA:43556,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:83420,
CC         ChEBI:CHEBI:83422; Evidence={ECO:0000250|UniProtKB:O15357};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43557;
CC         Evidence={ECO:0000250|UniProtKB:O15357};
CC   -!- ACTIVITY REGULATION: Activated upon translocation to the sites of
CC       synthesis of PtdIns(3,4,5)P3 in the membrane. Enzymatic activity is
CC       enhanced in the presence of phosphatidylserine (By similarity).
CC       {ECO:0000250}.
CC   -!- SUBUNIT: Interacts with tyrosine phosphorylated form of SHC1 (By
CC       similarity). Interacts with EGFR (By similarity). Upon stimulation by
CC       the EGF signaling pathway, it forms a complex with SHC1 and EGFR (By
CC       similarity). Interacts with cytoskeletal protein SORBS3/vinexin,
CC       promoting its localization to the periphery of cells (By similarity).
CC       Forms a complex with filamin (FLNA or FLNB), actin, GPIb (GP1BA or
CC       GP1BB) that regulates cortical and submembraneous actin (By
CC       similarity). Interacts with c-Met/MET, when c-Met/MET is phosphorylated
CC       on 'Tyr-1356' (By similarity). Interacts with p130Cas/BCAR1 (By
CC       similarity). Interacts with CENTD3/ARAP3 via its SAM domain (By
CC       similarity). Interacts with c-Cbl/CBL and CAP/SORBS1 (By similarity).
CC       Interacts with activated EPHA2 receptor (By similarity). Interacts with
CC       receptors FCGR2A (By similarity). Interacts with FCGR2B (By
CC       similarity). Interacts with tyrosine kinase ABL1 (By similarity).
CC       Interacts with tyrosine kinase TEC (By similarity). Interacts with
CC       CSF1R (By similarity). Interacts (via N-terminus) with SH3YL1 (via SH3
CC       domain) (By similarity). Interacts (via SH2 domain) with tyrosine
CC       phosphorylated KLRC1 (via ITIM) (By similarity). Interacts with
CC       NEDD9/HEF1 (By similarity). {ECO:0000250|UniProtKB:F1PNY0,
CC       ECO:0000250|UniProtKB:O15357, ECO:0000250|UniProtKB:Q6P549}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol {ECO:0000269|PubMed:12351701}.
CC       Cytoplasm, cytoskeleton {ECO:0000250}. Membrane
CC       {ECO:0000269|PubMed:12351701}; Peripheral membrane protein
CC       {ECO:0000269|PubMed:12351701}. Cell projection, filopodium
CC       {ECO:0000250|UniProtKB:O15357}. Cell projection, lamellipodium
CC       {ECO:0000250|UniProtKB:O15357}. Basal cell membrane
CC       {ECO:0000250|UniProtKB:F1PNY0}. Nucleus {ECO:0000250|UniProtKB:D7PF45}.
CC       Nucleus speckle {ECO:0000250|UniProtKB:D7PF45}. Cytoplasm,
CC       cytoskeleton, spindle pole {ECO:0000250|UniProtKB:F1PNY0}.
CC       Note=Translocates to membrane ruffles when activated, translocation is
CC       probably due to different mechanisms depending on the stimulus and cell
CC       type. Partly translocated via its SH2 domain which mediates interaction
CC       with tyrosine phosphorylated receptors such as the FC-gamma-RIIB
CC       receptor (FCGR2B). Tyrosine phosphorylation may also participate in
CC       membrane localization. Insulin specifically stimulates its
CC       redistribution from the cytosol to the plasma membrane. Recruited to
CC       the membrane following M-CSF stimulation. In activated spreading
CC       platelets, localizes with actin at filopodia, lamellipodia and the
CC       central actin ring.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9WVR3-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9WVR3-2; Sequence=VSP_027986;
CC   -!- DOMAIN: The SH2 domain interacts with tyrosine phosphorylated forms of
CC       proteins such as SHC1 or FCGR2A (By similarity). It also mediates the
CC       interaction with p130Cas/BCAR1 (By similarity).
CC       {ECO:0000250|UniProtKB:O15357}.
CC   -!- DOMAIN: The NPXY sequence motif found in many tyrosine-phosphorylated
CC       proteins is required for the specific binding of the PID domain.
CC       {ECO:0000250|UniProtKB:Q9ES52}.
CC   -!- PTM: Tyrosine phosphorylated by the members of the SRC family after
CC       exposure to a diverse array of extracellular stimuli such as insulin,
CC       growth factors such as EGF or PDGF, chemokines, integrin ligands and
CC       hypertonic and oxidative stress. May be phosphorylated upon IgG
CC       receptor FCGR2B-binding. Phosphorylated at Tyr-987 following cell
CC       attachment and spreading. Phosphorylated at Tyr-1161 following EGF
CC       signaling pathway stimulation (By similarity). {ECO:0000250}.
CC   -!- POLYMORPHISM: Variant Cys-1142 found in diabetic GK strain may be a
CC       cause of diabete in this strain. Genetic variations in Inppl1 may also
CC       be a cause of susceptibility to hypertension.
CC       {ECO:0000269|PubMed:12086927}.
CC   -!- SIMILARITY: Belongs to the inositol 1,4,5-trisphosphate 5-phosphatase
CC       family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB011439; BAA81818.1; -; mRNA.
DR   EMBL; AB025794; BAA82308.1; -; mRNA.
DR   RefSeq; NP_001257772.1; NM_001270843.1. [Q9WVR3-2]
DR   RefSeq; NP_075233.1; NM_022944.2. [Q9WVR3-1]
DR   AlphaFoldDB; Q9WVR3; -.
DR   BMRB; Q9WVR3; -.
DR   SMR; Q9WVR3; -.
DR   IntAct; Q9WVR3; 2.
DR   STRING; 10116.ENSRNOP00000061371; -.
DR   BindingDB; Q9WVR3; -.
DR   ChEMBL; CHEMBL2331062; -.
DR   iPTMnet; Q9WVR3; -.
DR   PhosphoSitePlus; Q9WVR3; -.
DR   jPOST; Q9WVR3; -.
DR   PaxDb; 10116-ENSRNOP00000061371; -.
DR   Ensembl; ENSRNOT00000066915.4; ENSRNOP00000061371.4; ENSRNOG00000019730.8. [Q9WVR3-2]
DR   GeneID; 65038; -.
DR   KEGG; rno:65038; -.
DR   UCSC; RGD:68396; rat. [Q9WVR3-1]
DR   AGR; RGD:68396; -.
DR   CTD; 3636; -.
DR   RGD; 68396; Inppl1.
DR   eggNOG; KOG0565; Eukaryota.
DR   eggNOG; KOG4384; Eukaryota.
DR   InParanoid; Q9WVR3; -.
DR   OrthoDB; 21647at2759; -.
DR   PhylomeDB; Q9WVR3; -.
DR   TreeFam; TF323475; -.
DR   Reactome; R-RNO-1660499; Synthesis of PIPs at the plasma membrane.
DR   Reactome; R-RNO-1855204; Synthesis of IP3 and IP4 in the cytosol.
DR   Reactome; R-RNO-912526; Interleukin receptor SHC signaling.
DR   PRO; PR:Q9WVR3; -.
DR   Proteomes; UP000002494; Chromosome 1.
DR   GO; GO:0009925; C:basal plasma membrane; ISS:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; ISO:RGD.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0030175; C:filopodium; IEA:UniProtKB-SubCell.
DR   GO; GO:0030027; C:lamellipodium; IDA:RGD.
DR   GO; GO:0016607; C:nuclear speck; ISS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; ISO:RGD.
DR   GO; GO:0000922; C:spindle pole; ISS:UniProtKB.
DR   GO; GO:0003779; F:actin binding; IEA:UniProtKB-KW.
DR   GO; GO:0004445; F:inositol-polyphosphate 5-phosphatase activity; IDA:RGD.
DR   GO; GO:0034485; F:phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase activity; IEA:UniProtKB-EC.
DR   GO; GO:0005547; F:phosphatidylinositol-3,4,5-trisphosphate binding; IDA:RGD.
DR   GO; GO:0042169; F:SH2 domain binding; ISO:RGD.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:UniProtKB-KW.
DR   GO; GO:0007015; P:actin filament organization; ISO:RGD.
DR   GO; GO:0006915; P:apoptotic process; ISO:RGD.
DR   GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW.
DR   GO; GO:0044255; P:cellular lipid metabolic process; ISO:RGD.
DR   GO; GO:0001958; P:endochondral ossification; ISS:UniProtKB.
DR   GO; GO:0006897; P:endocytosis; ISO:RGD.
DR   GO; GO:0070371; P:ERK1 and ERK2 cascade; ISO:RGD.
DR   GO; GO:0000132; P:establishment of mitotic spindle orientation; ISS:UniProtKB.
DR   GO; GO:0010467; P:gene expression; ISO:RGD.
DR   GO; GO:0006006; P:glucose metabolic process; ISO:RGD.
DR   GO; GO:0002376; P:immune system process; IEA:UniProtKB-KW.
DR   GO; GO:0032957; P:inositol trisphosphate metabolic process; IDA:RGD.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; ISO:RGD.
DR   GO; GO:0008156; P:negative regulation of DNA replication; IMP:RGD.
DR   GO; GO:0010629; P:negative regulation of gene expression; ISO:RGD.
DR   GO; GO:0046627; P:negative regulation of insulin receptor signaling pathway; IMP:RGD.
DR   GO; GO:0043569; P:negative regulation of insulin-like growth factor receptor signaling pathway; IMP:RGD.
DR   GO; GO:0010977; P:negative regulation of neuron projection development; IMP:RGD.
DR   GO; GO:0010642; P:negative regulation of platelet-derived growth factor receptor signaling pathway; IMP:RGD.
DR   GO; GO:0043491; P:phosphatidylinositol 3-kinase/protein kinase B signal transduction; ISO:RGD.
DR   GO; GO:0006661; P:phosphatidylinositol biosynthetic process; ISO:RGD.
DR   GO; GO:0046856; P:phosphatidylinositol dephosphorylation; IEA:InterPro.
DR   GO; GO:0009791; P:post-embryonic development; ISO:RGD.
DR   GO; GO:0110053; P:regulation of actin filament organization; ISS:UniProtKB.
DR   GO; GO:0050776; P:regulation of immune response; IBA:GO_Central.
DR   GO; GO:0032880; P:regulation of protein localization; ISS:UniProtKB.
DR   GO; GO:0032868; P:response to insulin; ISO:RGD.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IEP:RGD.
DR   GO; GO:0097178; P:ruffle assembly; ISO:RGD.
DR   CDD; cd09101; INPP5c_SHIP2-INPPL1; 1.
DR   CDD; cd09491; SAM_Ship2; 1.
DR   CDD; cd10343; SH2_SHIP; 1.
DR   Gene3D; 3.60.10.10; Endonuclease/exonuclease/phosphatase; 1.
DR   Gene3D; 3.30.505.10; SH2 domain; 1.
DR   Gene3D; 1.10.150.50; Transcription Factor, Ets-1; 1.
DR   InterPro; IPR036691; Endo/exonu/phosph_ase_sf.
DR   InterPro; IPR000300; IPPc.
DR   InterPro; IPR001660; SAM.
DR   InterPro; IPR013761; SAM/pointed_sf.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   PANTHER; PTHR46051:SF2; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE 5-PHOSPHATASE 2; 1.
DR   PANTHER; PTHR46051; SH2 DOMAIN-CONTAINING PROTEIN; 1.
DR   Pfam; PF22669; Exo_endo_phos2; 1.
DR   Pfam; PF00536; SAM_1; 1.
DR   Pfam; PF00017; SH2; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   SMART; SM00128; IPPc; 1.
DR   SMART; SM00454; SAM; 1.
DR   SMART; SM00252; SH2; 1.
DR   SUPFAM; SSF56219; DNase I-like; 1.
DR   SUPFAM; SSF47769; SAM/Pointed domain; 1.
DR   SUPFAM; SSF55550; SH2 domain; 1.
DR   PROSITE; PS50105; SAM_DOMAIN; 1.
DR   PROSITE; PS50001; SH2; 1.
PE   1: Evidence at protein level;
KW   Actin-binding; Alternative splicing; Cell adhesion; Cell membrane;
KW   Cell projection; Cytoplasm; Cytoskeleton; Hydrolase; Immunity;
KW   Lipid metabolism; Membrane; Nucleus; Phosphoprotein; Reference proteome;
KW   SH2 domain; SH3-binding.
FT   CHAIN           1..1257
FT                   /note="Phosphatidylinositol 3,4,5-trisphosphate 5-
FT                   phosphatase 2"
FT                   /id="PRO_0000302872"
FT   DOMAIN          21..117
FT                   /note="SH2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00191"
FT   DOMAIN          1195..1257
FT                   /note="SAM"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00184"
FT   REGION          119..181
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          897..986
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1004..1115
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           945..950
FT                   /note="SH3-binding"
FT   MOTIF           984..987
FT                   /note="NPXY motif"
FT   COMPBIAS        120..140
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        939..953
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1049..1065
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1089..1105
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         132
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         165
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:O15357"
FT   MOD_RES         241
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O15357"
FT   MOD_RES         353
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O15357"
FT   MOD_RES         887
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:O15357"
FT   MOD_RES         891
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O15357"
FT   MOD_RES         987
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:O15357"
FT   MOD_RES         1132
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O15357"
FT   MOD_RES         1136
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:O15357"
FT   MOD_RES         1161
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:O15357"
FT   MOD_RES         1256
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O15357"
FT   VAR_SEQ         1184..1257
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10381377"
FT                   /id="VSP_027986"
FT   VARIANT         1142
FT                   /note="R -> C (in strain: GK)"
FT                   /evidence="ECO:0000269|PubMed:12086927"
FT   MUTAGEN         987
FT                   /note="Y->F: Loss of phosphorylation following insulin
FT                   stimulation."
FT                   /evidence="ECO:0000269|PubMed:12351701"
FT   CONFLICT        910
FT                   /note="S -> N (in Ref. 1; BAA81818)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1009
FT                   /note="P -> L (in Ref. 1; BAA81818)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1257 AA;  139143 MW;  3A994C8E52940083 CRC64;
     MASVCGAPSP GGALGSQAPA WYHRDLSRAA AEELLARAGR DGSFLVRDSE SVAGAFALCV
     LYQKHVHTYR ILPDGEDFLA VQTSQGVPVR RFQTLGELIG LYAQPNQGLV CALLLPVEGE
     REPDPPDDRD ASDVEDEKPP LPPRSGSTSI SVPAGPSSPL PAPETPTTPA AESTPNGLST
     VSHEYLKGSY GLDLEAVRGG ASNLPHLTRT LVTSCRRLHS EVDKVLSGLE ILSKVFDQQS
     SPMVTRLLQQ QSLPQTGEQE LESLVLKLSV LKDFLSGIQK KALKALQDMS STAPPAPLQP
     SIRKAKTIPV QAFEVKLDVT LGDLTKIGKS QKFTLSVDVE GGRLVLLRRQ RDSQEDWTTF
     THDRIRQLIK SQRVQNKLGV VFEKEKDRTQ RKDFIFVSAR KREAFCQLLQ LMKNKHSKQD
     EPDMISVFIG TWNMGSVPPP KNVTSWFTSK GLGKALDEVT VTIPHDIYVF GTQENSVGDR
     EWLDLLRGGL KELTDLDYRP IAMQSLWNIK VAVLVKPEHE NRISHVSTSS VKTGIANTLG
     NKGAVGVSFM FNGTSFGFVN CHLTSGNEKT TRRNQNYLDI LRLLSLGDRQ LSAFDISLRF
     THLFWFGDLN YRLDMDIQEI LNYISRREFE PLLRVDQLNL EREKHKVFLR FSEEEISFPP
     TYRYERGSRD TYAWHKQKPT GVRTNVPSWC DRILWKSYPE THIICNSYGC TDDIVTSDHS
     PVFGTFEVGV TSQFISKKGL SKTSDQAYIE FESIEAIVKT ASRTKFFIEF YSTCLEEYKK
     SFENDAQSSD NINFLKVQWS SRQLPTLKPI LADIEYLQDQ HLLLTVKSMD GYESYGECVV
     ALKSMIGSTA QQFLTFLSHR GEETGNIRGS MKVRVPTERL GTRERLYEWI SIDKDDTGAK
     SKAPSVLRGS QEHRSGSRKP TSTEASCPLS KLFEEPEKPP PTGRPPAPPR AVPREESLNP
     RLKSEGTPEQ EGVAAPPPKN SFNNPAYYVL EGVPHQLLPL EPTSFARAPI PPTTKNKVAI
     TVPAPQLGRH RTPRVGEGSS SDEDSGGTLP PPDFPPPPLP DSAIFLPPNL DPLSMPVVRG
     RSVGEARGPP PPKAHPRPPL PPGTSPASTF LEEVASADDR SCSVLQMAKT LSEVDYSPGP
     GRSALLPNPL ELQLPRGPSD YGRPLSFPPP RIRESIQEDL AEEAPCPQGG RASGLGEAGM
     GAWLRAIGLE RYEEGLVHNG WDDLEFLSDI TEEDLEEAGV QDPAHKRLLL DTLQLSK
//
